Bleomycin Inhibits Clec14a To Attenuate The Progression Of Extracranial Arteriovenous Malformation
Congzhen Qiao, Yun Zou, MD, Yunbo Jin, MD,PhD, Xiaoxi Lin, MD, PhD.
Shanghai Ninth People's Hospital, Shanghai, China.
We previously reported that interstitial injection of bleomycin (BLM) reduces the size of early-stage extracranial AVM. Here we seek to investigate the potential mechanisms of BLM in treating extracranial arteriovenous malformation.
Samples of human extracranial AVM (n=3) with no pharmacological treatment were harvested. AVM endothelial cells were isolated and underwent primary cell culture. The transcriptome was detected by RNA-sequencing and differentially expressed CLEC14A were validated at transcriptomic as well as protein level. Immunocytochemical staining of CLEC14A was performed in samples of human extracranial AVM with or without BLM treatment.
Through second-generation sequencing, we found that there are 5,689 genes that are differentially increased or decreased upon 24-hour bleomycin stimulation. We found that CLEC14A may play an important role in the progression of arteriovenous malformations and can be inhibited by BLM treatment.
Bleomycin inhibits CLEC14A expression to attenuate the progression of AVM.
Back to 2020 ePosters